What do CEOs owe the world?
It was a controversial choice for Annovis Bio to change the endpoint of a Phase 3 Parkinson’s trial at the last minute. STAT’s Adam Feuerstein, ever skeptical, reached out to…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we discuss how the FDA is holding firm in how it handles non-compliant trial sponsors and investigators, how PhRMA is rebuilding its ranks, and offer up a fabulous podcast.
What's Your Reaction?
